100 related articles for article (PubMed ID: 8765492)
1. Hematologic side effects of radiolabeled immunoglobulin therapy.
Vriesendorp HM; Quadri SM; Andersson BS; Dicke KA
Exp Hematol; 1996 Aug; 24(10):1183-90. PubMed ID: 8765492
[TBL] [Abstract][Full Text] [Related]
2. Selection of reagents for human radioimmunotherapy.
Vriesendorp HM; Quadri SM; Stinson RL; Onyekwere OC; Shao Y; Klein JL; Leichner PK; Williams JR
Int J Radiat Oncol Biol Phys; 1992; 22(1):37-45. PubMed ID: 1727128
[TBL] [Abstract][Full Text] [Related]
3. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
Denardo SJ; Richman CM; Goldstein DS; Shen S; Salako Q; Kukis DL; Meares CF; Yuan A; Welborn JL; Denardo GL
Anticancer Res; 1997; 17(3B):1735-44. PubMed ID: 9179227
[TBL] [Abstract][Full Text] [Related]
4. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease.
Vriesendorp HM; Morton JD; Quadri SM
Cancer Res; 1995 Dec; 55(23 Suppl):5888s-5892s. PubMed ID: 7493365
[TBL] [Abstract][Full Text] [Related]
5. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
6. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
7. gamma-Interferon administration after 90yttrium radiolabeled antibody therapy: survival and hematopoietic toxicity studies.
Thomas GE; Esteban JM; Raubitschek A; Wong JY
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):529-34. PubMed ID: 7852116
[TBL] [Abstract][Full Text] [Related]
8. Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy.
O'Donoghue JA; Baidoo N; Deland D; Welt S; Divgi CR; Sgouros G
Cancer Biother Radiopharm; 2002 Aug; 17(4):435-43. PubMed ID: 12396707
[TBL] [Abstract][Full Text] [Related]
9. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
Juweid ME; Zhang CH; Blumenthal RD; Hajjar G; Sharkey RM; Goldenberg DM
J Nucl Med; 1999 Oct; 40(10):1609-16. PubMed ID: 10520699
[TBL] [Abstract][Full Text] [Related]
10. Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy.
Wilder RB; DeNardo GL; Sheri S; Fowler JF; Wessels BW; DeNardo SJ
Eur J Nucl Med; 1996 Aug; 23(8):953-7. PubMed ID: 8753685
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
[TBL] [Abstract][Full Text] [Related]
13. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
[TBL] [Abstract][Full Text] [Related]
14. Evaluating changes in stable chromosomal translocation frequency in patients receiving radioimmunotherapy.
Wong JY; Wang J; Liu A; Odom-Maryon T; Shively JE; Raubitschek AA; Williams LE
Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):599-607. PubMed ID: 10701739
[TBL] [Abstract][Full Text] [Related]
15. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3).
DeNardo GL; Kroger LA; DeNardo SJ; Miers LA; Salako Q; Kukis DL; Fand I; Shen S; Renn O; Meares CF
Cancer; 1994 Feb; 73(3 Suppl):1012-22. PubMed ID: 8306243
[TBL] [Abstract][Full Text] [Related]
16. Combined radioimmunotherapy and chemotherapy of human colon carcinoma grafted in nude mice, advantages and limitations.
Chalandon Y; Mach JP; Pèlegrin A; Folli S; Buchegger F
Anticancer Res; 1992; 12(4):1131-9. PubMed ID: 1503403
[TBL] [Abstract][Full Text] [Related]
17. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
18. Prediction of myelotoxicity using semi-quantitative marrow image scores.
Lim S; DeNardo GL; DeNardo DA; O'Donnell RT; Yuan A; DeNardo SJ
J Nucl Med; 1997 Nov; 38(11):1749-53. PubMed ID: 9374345
[TBL] [Abstract][Full Text] [Related]
19. Myelosuppressive changes from single or repeated doses of radioantibody therapy: effect of bone marrow transplantation, cytokines, and hematopoietic suppression.
Blumenthal RD; Alisauskas R; Lew W; Sharkey RM; Goldenberg DM
Exp Hematol; 1998 Aug; 26(9):859-68. PubMed ID: 9694507
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.
Stewart JS; Hird V; Snook D; Sullivan M; Myers MJ; Epenetos AA
Int J Cancer Suppl; 1988; 3():71-6. PubMed ID: 3209303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
